Browse PIK3CD

Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00454 Phosphatidylinositol 3- and 4-kinase
PF00792 Phosphoinositide 3-kinase C2
PF02192 PI3-kinase family
PF00794 PI3-kinase family
PF00613 Phosphoinositide 3-kinase family
Function

Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.

> Gene Ontology
 
Biological Process GO:0001779 natural killer cell differentiation
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002521 leukocyte differentiation
GO:0002551 mast cell chemotaxis
GO:0002573 myeloid leukocyte differentiation
GO:0002679 respiratory burst involved in defense response
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006644 phospholipid metabolic process
GO:0006650 glycerophospholipid metabolic process
GO:0006661 phosphatidylinositol biosynthetic process
GO:0006887 exocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0008654 phospholipid biosynthetic process
GO:0010818 T cell chemotaxis
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030101 natural killer cell activation
GO:0030217 T cell differentiation
GO:0030258 lipid modification
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032418 lysosome localization
GO:0035747 natural killer cell chemotaxis
GO:0035754 B cell chemotaxis
GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process
GO:0040017 positive regulation of locomotion
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0043299 leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0045017 glycerolipid biosynthetic process
GO:0045055 regulated exocytosis
GO:0045123 cellular extravasation
GO:0045576 mast cell activation
GO:0045730 respiratory burst
GO:0046474 glycerophospholipid biosynthetic process
GO:0046486 glycerolipid metabolic process
GO:0046488 phosphatidylinositol metabolic process
GO:0046834 lipid phosphorylation
GO:0046854 phosphatidylinositol phosphorylation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048247 lymphocyte chemotaxis
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050900 leukocyte migration
GO:0051272 positive regulation of cellular component movement
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0060326 cell chemotaxis
GO:0060374 mast cell differentiation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071621 granulocyte chemotaxis
GO:0072672 neutrophil extravasation
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0097531 mast cell migration
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
Molecular Function GO:0016303 1-phosphatidylinositol-3-kinase activity
GO:0016307 phosphatidylinositol phosphate kinase activity
GO:0035004 phosphatidylinositol 3-kinase activity
GO:0035005 1-phosphatidylinositol-4-phosphate 3-kinase activity
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity
GO:0052742 phosphatidylinositol kinase activity
GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component GO:0005942 phosphatidylinositol 3-kinase complex
GO:0019898 extrinsic component of membrane
GO:0042629 mast cell granule
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04210 Apoptosis
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04611 Platelet activation
hsa04620 Toll-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04668 TNF signaling pathway
hsa04670 Leukocyte transendothelial migration
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04915 Estrogen signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04960 Aldosterone-regulated sodium reabsorption
hsa04973 Carbohydrate digestion and absorption
hsa00562 Inositol phosphate metabolism
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-180292: GAB1 signalosome
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-1483255: PI Metabolism
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-1483257: Phospholipid metabolism
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-8853659: RET signaling
R-HSA-912631: Regulation of signaling by CBL
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-1660499: Synthesis of PIPs at the plasma membrane
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PIK3CD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PIK3CD and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27656909Melanoma; Breast CarcinomaInhibit immunity; immunotherapy targetThe combinations of nanoscale MEK- and PI3K-targeting supramolecular therapeutics with checkpoint PDL1 and PD1 inhibitors exert enhanced antitumor outcome in melanoma and breast cancers in vivo, respectively.
22364281Acute Lymphoblastic Leukemia; LymphomaInhibit immunity (T cell function); immunotherapy targetGenetic and pharmacological experiments have shown that PI3K activation regulates many steps in the development, activation and differentiation of both B- and T-cells. An exciting discovery is that a selective inhibitor of the p110δ catalytic isoform of PI3K, CAL-101, achieves impressive clinical efficacy in certain B-cell malignancies. A model is emerging in which p110δ inhibition disrupts signals from the lymphoid microenvironment, leading to release of leukaemia and lymphoma cells from their protective niche.
24919154leukaemiaInhibit immunity (T cell function); immunotherapy targetWe demonstrate that p110δ inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression.
21441454MelanomaInhibit immunityInteraction of LAG-3 with MHC II expressed on melanoma cells upregulates both MAPK/Erk and PI3K/Akt pathways, albeit with different kinetics. Inhibition studies using specific inhibitors of both pathways provided evidence of their involvement in the LAG-3-induced protection from apoptosis.
28108509Lung CarcinomaInhibit immunity; Resistant to immunotherapyConversely, PI3Kδ was functionally critical in Treg, acting there to control T-cell receptor signaling, cell proliferation, and survival. Notably, in a murine model of lung cancer, coadministration of a PI3Kδ-specific inhibitor with a tumor-specific vaccine decreased numbers of suppressive Treg and increased numbers of vaccine-induced CD8 T cells within the tumor microenvironment, eliciting potent antitumor efficacy.
25080445Melanoma; Colon Carcinoma; LymphomaInhibit immunityFurthermore, these PI3K-Akt inhibitors led to a significant therapeutic antitumor effect, which was shown to be Treg dependent. Here, we report the use of PI3K-Akt pathway inhibitors as potent agents for the selective depletion of suppressive Tregs. We found that PI3K-Akt pathway inhibitors selectively inhibit Tregs with minimal effect on conventional T cells
16849475lymphomaPromote immunityThis activity evidently derives from a 25-kDa fragment of beta-glucan released by macrophage processing of the parent polysaccharide. This fragment, but not parent beta-glucan, binds to neutrophil CR3, induces CBRM 1/5 neoepitope expression, and elicits CR3-dependent cytotoxicity. Thus, beta-glucan enhances tumor killing through a cascade of events, including in vivo macrophage cleavage of the polysaccharide, dual CR3 ligation, and CR3-Syk-PI3K signaling. These results are important inasmuch as beta-glucan, an agent without evident toxicity, may be used to amplify tumor cell killing and may open new opportunities in the immunotherapy of cancer.
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PIK3CD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PIK3CD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1720.683
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4640.424
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7720.574
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2450.587
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0840.964
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.670.797
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3110.45
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5730.723
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0170.992
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.6050.139
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2540.467
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1740.257
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PIK3CD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIK3CD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIK3CD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIK3CD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIK3CD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PIK3CD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PIK3CD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPIK3CD
Namephosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location1p36.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PIK3CD collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PIK3CD.
ID Name Drug Type Targets #Targets
DB00201CaffeineSmall MoleculeADORA1, ADORA2A, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, ......33
DB05241XL765Small MoleculeMTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG5
DB068312-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONESmall MoleculePIK3CD, PIK3CG2
DB12483CopanlisibSmall MoleculePIK3CA, PIK3CD2